Novan, Inc. is a medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a current focus on molluscum contagiosum, or molluscum. In the first quarter of 2022, we completed the EPI Health Acquisition. EPI Health equips us with a commercial infrastructure across sales, marketing, and communications, as well as a dedicated market access and pharmacy relations team, and positions us as a fully integrated dermatology company with a pipeline of development candidates focused primarily on dermatological indications supported by a commercial platform to market and sell therapeutic products for skin diseases.
Company profile
Ticker
NOVNQ
Exchange
Website
CEO
Paula Stafford
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Novan, Inc.
SEC CIK
Corporate docs
Subsidiaries
EPI Health, LLC ...
NOVNQ stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
25 Mar 24
8-K
Regulation FD Disclosure
26 Feb 24
8-K
Bankruptcy or Receivership
30 Jan 24
8-K
Regulation FD Disclosure
26 Jan 24
8-K
Regulation FD Disclosure
21 Dec 23
8-K
Regulation FD Disclosure
22 Nov 23
8-K
Regulation FD Disclosure
24 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Oct 23
8-K
Completion of Acquisition or Disposition of Assets
27 Sep 23
8-K
Completion of Acquisition or Disposition of Assets
27 Sep 23
Transcripts
NOVNQ
Earnings call transcript
2023 Q1
15 May 23
NOVNQ
Earnings call transcript
2022 Q4
30 Mar 23
NOVNQ
Earnings call transcript
2022 Q3
14 Nov 22
NOVNQ
Earnings call transcript
2022 Q2
12 Aug 22
NOVNQ
Earnings call transcript
2022 Q1
16 May 22
NOVNQ
Earnings call transcript
2021 Q4
22 Feb 22
NOVNQ
Earnings call transcript
2021 Q3
10 Nov 21
NOVNQ
Earnings call transcript
2021 Q2
12 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.77 mm | 13.77 mm | 13.77 mm | 13.77 mm | 13.77 mm | 13.77 mm |
Cash burn (monthly) | 59.33 k | 1.86 mm | 4.69 mm | 2.92 mm | 1.42 mm | 2.99 mm |
Cash used (since last report) | 749.00 k | 23.47 mm | 59.18 mm | 36.89 mm | 17.88 mm | 37.76 mm |
Cash remaining | 13.02 mm | -9.70 mm | -45.41 mm | -23.12 mm | -4.12 mm | -24.00 mm |
Runway (months of cash) | 219.4 | -5.2 | -9.7 | -7.9 | -2.9 | -8.0 |
Institutional ownership, Q2 2023
9.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 3 |
Closed positions | 5 |
Increased positions | 9 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 816.00 mm |
Total shares | 2.78 mm |
Total puts | 0.00 |
Total calls | 3.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 807.99 k | $347.44 mm |
Reedy Creek Investments | 789.47 k | $8.20 mm |
BLK Blackrock | 329.12 k | $141.52 mm |
Geode Capital Management | 234.56 k | $100.86 mm |
National Asset Management | 192.90 k | $82.95 mm |
Renaissance Technologies | 94.10 k | $40.00 k |
STT State Street | 54.67 k | $23.51 mm |
Citadel Advisors | 49.36 k | $21.23 mm |
Creative Planning | 36.00 k | $15.48 mm |
NTRS Northern Trust | 34.12 k | $14.67 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 23 | Machelle Sanders | Common Stock | Sell | Dispose S | No | No | 0.4082 | 11,553 | 4.72 k | 25,248 |
7 Jun 23 | Steven D Skolsky | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,101 | 0.00 | 36,101 |
7 Jun 23 | Steven D Skolsky | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 36,101 | 0.00 | 0 |
7 Jun 23 | Geer W Kent | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,101 | 0.00 | 37,683 |
7 Jun 23 | Geer W Kent | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 36,101 | 0.00 | 0 |
7 Jun 23 | Machelle Sanders | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,101 | 0.00 | 36,801 |
7 Jun 23 | Machelle Sanders | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 36,101 | 0.00 | 0 |
7 Jun 23 | Bierman James L | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,101 | 0.00 | 40,101 |
7 Jun 23 | Bierman James L | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 36,101 | 0.00 | 0 |
6 Jun 23 | Steven D Skolsky | RSU Common Stock | Grant | Acquire A | No | No | 0 | 103,092 | 0.00 | 103,092 |